



Original Research Article

Effects of yeast cell wall on growth performance, immune responses and intestinal short chain fatty acid concentrations of broilers in an experimental necrotic enteritis model

Guang-Da Xue, Shu-Biao Wu, Mingan Choct, Robert A. Swick*

Animal Science, School of Environmental and Rural Sciences, University of New England, Armidale, NSW 2351, Australia

ARTICLE INFO

Article history:

Received 9 March 2017

Received in revised form

23 June 2017

Accepted 5 August 2017

Available online 18 August 2017

Keywords:

Subclinical necrotic enteritis

Yeast cell wall extract

Immune response

Short chain fatty acid

Broiler

ABSTRACT

Subclinical necrotic enteritis (NE) causes devastating economic losses in the broiler chicken industry, especially in birds raised free of in-feed antibiotics. Probiotics are potential alternatives to in-feed antibiotics. Yeast cell wall extract (YCW) derived from *Saccharomyces cerevisiae* is a prebiotic with known immune modulating effects. This study examined the effects of YCW and antibiotics (AB) during sub-clinical NE on broiler growth performance, intestinal lesions, humoral immune response and gut microflora metabolites. The study employed a 2×3 factorial arrangement of treatments. Factors were: NE challenge (yes or no) and feed additive (control, AB, or YCW). Each treatment was replicated in 8 floor pens with 15 birds per pen. Challenged birds had higher feed conversion ratio (FCR) than unchallenged birds on d 35 ($P < 0.05$). Dietary inclusion of AB decreased FCR regardless of challenge ($P < 0.05$) on d 24 and 35. Inclusion of YCW reduced serum interleukin-1 (IL-1) concentration in NE challenged birds ($P < 0.01$) and increased immunoglobulin (Ig) G ($P < 0.05$) and Ig M ($P < 0.05$) levels compared to other dietary treatments regardless of challenge. Yeast cell wall extract increased formic acid concentration in cecal contents during challenge and increased butyric acid concentration in unchallenged birds on d 16. This study indicates YCW suppressed inflammatory response, promoted generation of immunoglobulin and increased short chain fatty acid production suggesting potential benefits to bird health.

© 2017, Chinese Association of Animal Science and Veterinary Medicine. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Necrotic enteritis (NE) caused by *Clostridium perfringens* (Cp) is an economically important disease of the broiler industry. In-feed antibiotics have largely controlled NE. The ban of in-feed antibiotics in the European Union has resulted in an increased incidence of NE (Shojadoost et al., 2012). This disease is estimated to cost the global poultry industry approximately 6 billion US dollars annually (Wade and Keyburn, 2015) with the subclinical form of this disease

more devastating than the acute form (Timbermont et al., 2011). Subclinical NE persists in flocks without detectable clinical signs and results in a drag on performance, i.e., lower weight gain and increased feed conversion ratio (FCR), due to poor digestion and absorption of nutrients (Van der Sluis, 2000; Kaldhusdal et al., 2001). There is current heightened interest in replacements for in-feed antibiotics to control subclinical NE.

Yeast cell walls (YCW) contain mannoproteins, β (1,3)-glucans, β (1,6)-glucans, chitin and glycopospholipid surface proteins associated with the plasma membrane. The YCW is known to have prebiotic properties with efficacy for modulating immunity and gut microflora (Pourabedin and Zhao, 2015). As such, YCW is a potential replacement for dietary sub-therapeutic antibiotic. Immunomodulation has been suggested to be the key mode of action of YCW (Shashidhara and Devegowda, 2003; Gao et al., 2008). Probiotics derived from YCW have been found to promote the production of immunoglobulin (Ig) (Czech et al., 2010) that plays as an important part in host immunity. By recognizing and binding particular antigens, Ig controls the prevalence and severity of infections

* Corresponding author.

E-mail address: rswick@une.edu.au (R.A. Swick).

Peer review under responsibility of Chinese Association of Animal Science and Veterinary Medicine.



(Goudswaard et al., 1977; Desmidt et al., 1998). Prebiotics derived from YCW were also found to prevent the disease by inducing the pro-inflammatory responses (Monsan and Paul, 2008) as inflammation mediates the host immunity to against the disease such as acute bacterial infection (Medzhitov, 2007). The mode of action of YCW also involves altering gut microflora composition via competitive exclusion (Callaway et al., 2008), production of antimicrobial agents (Chen et al., 2007; Muñoz et al., 2012) and changing the fermentation pattern of the gut microflora (Donalson et al., 2008).

A previous study showed improved performance of broilers under clinical NE with dietary addition of YCW (M'Sadeq et al., 2015). However, the effect of YCW during subclinical NE has not been investigated to the best of our knowledge. Therefore, the present study was designed to examine the role of YCW in performance, intestinal NE lesions, pro- and anti-inflammatory markers, Ig production and intestinal metabolite profile in the broiler chickens challenged by subclinical NE.

2. Materials and methods

This study was conducted at University of New England, Armidale, New South Wales, Australia. All experimental procedures and protocols involved in this study were reviewed and approved by the Animal Ethics Committee of the University of New England. Birds were cared for according to the Australian Code for the Care and Use of Animals for Scientific Purposes (8th Edition, 2013).

2.1. Experimental design, diet and bird husbandry

The Animal Ethics Committee of University of New England (Australia) reviewed and approved all experimental procedures involved in this study. Ross 308 male broiler chicks ($n = 720$) were obtained from a commercial hatchery (Baiada Hatchery, Tamworth, NSW, Australia). Birds were vaccinated against Marek's disease, infectious bronchitis and Newcastle disease at the hatchery. Chicks were weighed, allocated to floor pens (120 cm \times 75 cm per pen) such that starting pen weights were not different ($P > 0.05$). Fresh wood shavings were used as bedding. The environmentally controlled room was disinfected and preheated prior to chick arrival. The lighting and temperature program followed the breeder recommendations (Aviagen, 2014).

The study employed a 2 \times 3 factorial arrangement of treatments with 8 replicate pens per treatment and 15 birds per pen. Factors were: NE challenge (no or yes), and additive (none [control], YCW [Actigen, Alltech, USA; 800, 400, 200 g/t; starter, grower and finisher, respectively], or antibiotics [AB]). The AB treatment consisted of a combination of Zn bacitracin and salinomycin. Dosage was Albac G 150 (Zoetis Australia Pty Ltd, Rhodes, NSW) at 100 g/t starter, 50 g/t grower and finisher; Sacox 120 Microgranulate (Huvepharma, Burwood, VIC) at 60 g/t. The diets were based on wheat, soybean meal, sorghum, canola meal, meat and bone meal and formulated to meet Ross 308 nutrient specifications (Table 1). The starter diet was fed from d 0 to 10, grower from d 10 to 24 and finisher from d 24 to 35. The starter diet was crumbled to d 7 and thereafter pellets were fed (2.5 mm). Pellet temperature was 65 °C. Birds had *ad libitum* access to feed and water. Pen weight and cumulative pen feed intake were recorded on d 0, 24 and 35 and used to calculate mean bird weight gain (BWG), feed intake (FI) and FCR (corrected for mortality).

2.2. Necrotic enteritis challenge

On d 9, each bird in the NE-challenge group was given 1 mL per os vaccine strains of *Eimeria* (Bioproperties Pty Ltd., Sydney,

Table 1

Ingredient and nutrient composition of experimental basal diets (as-fed, % unless otherwise noted).

Item	Starter	Grower	Finisher
Ingredients			
Sorghum	20.0	20.0	20.0
Wheat	38.5	43.6	50.6
Soybean meal	26.2	18.1	10.5
Canola meal	5.0	7.0	7.0
Meat and bone meal	3.0	4.0	6.0
Canola oil	3.79	4.79	4.44
Limestone	0.83	0.63	0.32
CaHPO ₄ ¹	1.05	0.60	—
Allzyme SSF	0.20	0.20	0.20
NaCl	0.17	0.14	0.11
NaHCO ₃	0.20	0.15	0.15
Vitamin mineral premix ²	0.20	0.20	0.20
Choline chloride 60%	0.74	0.73	0.65
L-lysine	0.361	0.317	0.277
DL-methionine	0.358	0.289	0.214
L-threonine	0.199	0.165	0.128
Calculated composition			
ME, kcal/kg	3,025	3,150	3,200
Crude protein	22.5	20.6	19.3
DLys	1.27	1.10	0.94
DMet + DCys	0.94	0.84	0.73
DThr	0.83	0.073	0.63
Dlle	0.85	0.77	0.67
DArg	1.31	1.14	0.99
DVal	0.98	0.84	0.79
Crude fat	6.05	7.18	7.05
Crude fiber	2.63	2.65	2.59
Calcium	0.90	0.80	0.70
Available phosphorus	0.45	0.40	0.36
Total phosphorus	0.72	0.67	0.62
Sodium	0.18	0.16	0.16
Chloride	0.25	0.22	0.20
Choline	1,600	1,500	1,400
Linoleic acid	1.86	2.11	2.01

¹ Dicalcium phosphate contained: phosphorus, 18%; calcium, 21%.

² Vitamin and mineral concentrate supplied per kilogram diet: retinol, 12,000 IU; cholecalciferol, 5,000 IU; tocopheryl acetate, 75 mg; menadione, 3 mg; thiamine, 3 mg; riboflavin, 8 mg; niacin, 55 mg; pantothenate, 13 mg; pyridoxine, 5 mg; folate, 2 mg; cyanocobalamin, 16 µg; biotin, 200 µg; cereal-based carrier, 149 mg; mineral oil, 2.5 mg; Cu (sulfate), 16 mg; Fe (sulfate), 40 mg; I (iodide), 1.25 mg; Se (selenate), 0.3 mg; Mn (sulfate and oxide), 120 mg; Zn (sulfate and oxide), 100 mg.

Australia). Each 1 mL gavage included phosphate buffered saline (PBS) suspension of approximately 5,000 oocysts each of *Escherichia acervulina* and *Eimeria maxima*, and 2,500 oocysts of *Escherichia brunetti*. To the unchallenged group, 1 mL of sterile PBS was administered as control. On d 14 and 15, each bird in the NE-challenge group was given 1 mL of Cp suspension at a concentration of 10⁸ cfu/mL. A primary poultry isolate of Cp type A strain EHE-NE36 (CSIRO Livestock Industries, Geelong, Australia) was incubated overnight at 39 °C in 100 mL of sterile thioglycollate broth (USP alternative, Oxoid, Australia) followed by subsequent overnight incubations of 1 mL of the previous culture in 100 mL of sterilized cooked meat medium (Oxoid, Australia), and then in 500 mL of thioglycollate broth containing starch (10 g/L) and pancreatic digest of casein (5 g/L) to obtain the challenge inoculum. Birds in the unchallenged groups received 1 mL of sterile thioglycollate broth. Unchallenged and challenged birds were physically partitioned to prevent cross contamination.

2.3. Sampling and lesion scoring

On d 16, 2 birds per pen were randomly selected and euthanized by cervical dislocation. The liver was excised and weighed. The size of the liver was expressed relative to the whole bird body weight. Blood samples were collected in non-heparinized tubes by

puncturing the brachial vein and centrifuged at $2,000 \times g$ for 10 min to obtain serum. The ceca content and serum were pooled from 2 birds in each replicate pen and stored at -20°C until further analysis. The entire length of the section of small intestine (duodenum, jejunum and ileum) of all sampled birds underwent a lesion scoring process, based on a previously reported lesion scoring system that ranges from 0 to 4 (Prescott et al., 1978; Broussard et al., 1986). Three experienced personnel, with no knowledge of the trial design, were involved in the scoring process.

2.4. Serum interleukins and immunoglobulins ELISA assays

Commercially available ELISA kits were used to measure the serum interleukin-1 and 10 (IL-1, IL-10) and serum IgA, IgG and IgM in serum collected at d 16 following the manufacturer instructions (IL-1, IL-10 ELISA: Cusabio, Wuhan, China, catalog No. CSB-E10069Ch; CSB-E12835C; IgA, IgG and IgM ELISA: Abnova, Taipei, Taiwan, catalog No. KA2426; KA2031; KA2427).

2.5. Short chain fatty acids (SCFA)

Gas chromatography was used to analyze SCFA in the caecal content following the modified version of the method described by Jensen et al. (1995). One milliliter of internal standard (0.01 mol/L ethylbutyric acid) was added to approximately 2 g of fresh homogenized digesta sample and the solution was then mixed and centrifuged at $27,216 \times g$ at 5°C for 20 min. Approximately 1 mL of the resulting supernatant, 0.5 mL of concentrated HCl, and 2.5 mL of ether were then combined. An internal standard solution and a blank were also prepared using 1 mL of the standard acid mixture and 1 mL of water respectively in place of the supernatant. The mixture was then centrifuged at $2,000 \times g$ at 5°C for 15 min and 400 μL of the resulting supernatant was combined with 40 μL of *N*-tert-butylidimethylsilyl-*N*-methyltrifluoroacetamide. The samples were then heated at 80°C for 20 min, left at room temperature for 48 h and were then analyzed on a Varian CP3400 CX gas Chromatograph (Varian Analytical Instruments, Palo Alto, CA, USA). Short chain fatty acids concentrations were presented as $\mu\text{mol/g}$ digesta.

2.6. Statistical analysis

Statistical analysis was carried out using IBM SPSS Statistics package version 22 (IBM Corporation). The study employed a 2×3 factorial arrangement of treatments in a completely randomized design. Factors were NE challenge (no or yes), and additives (none, YCW and AB). Main effects and interactions were examined by analysis of variance, using the General Linear Model. Mortality and intestinal lesion score data were analyzed by the nonparametric Kruskal–Wallis test, as the data were not normally distributed. Treatment means were separated using Tukey HSD *post hoc* test where appropriate. Statistical significance was declared at $P < 0.05$.

3. Results

3.1. Performance

Table 2 shows BWG, FI, FCR and livability results from d 0 to 24. Challenge of NE negatively affected performance from d 0 to 24. Body weight gain of the challenged birds was 93% of that of the unchallenged birds (1,267 vs. 1,356 g, $P < 0.001$). Challenge had no impact on FI, but FCR was 6 points higher in challenged birds compared to controls ($P < 0.001$). There was a challenge \times additive interaction for weight gain ($P < 0.05$) from d 0 to 24. Feeding AB improved BWG in challenged birds and were not different to

unchallenged birds. Feed conversion ratio was also lower ($P < 0.01$) in the birds fed AB diets compared to those fed the control diet or diet with YCW. Treatment had no significant effect on livability from d 0 to 24.

Cumulative performance from d 0 to 35 is presented in Table 3. The long-term effect of NE was observed, as reflected by the higher FCR (3 points, $P < 0.05$) in the challenged compared to the unchallenged birds. Across challenge groups, FCR was 5 points lower in birds fed the diet supplemented with AB compared to those fed the control diet or diet with YCW ($P < 0.01$). Treatment had no effect on weight gain or FI from d 0 to 35. No challenge \times additive interactions were observed ($P > 0.05$).

3.2. Intestinal lesion scores

Intestinal lesion scores in the duodenum, jejunum and ileum measured at d 16 are presented in Table 4. Birds in all treatments had low lesions scores indicating the challenge was subclinical. However, a challenge \times additive interaction ($P < 0.01$) was detected, indicating higher ileal lesion scores in the challenged birds fed the control diet compared to the challenged birds fed the AB diet. Challenged birds fed YCW did not have different lesion scores from AB fed birds or control birds.

3.3. Humoral immune response and relative liver weights

Responses of cytokines (IL-1 and IL-10), Ig (IgA, IgG and IgM) in the peripheral blood and relative liver weights on d 16 are presented in Table 5. A challenge \times additive interaction ($P < 0.05$) was observed for serum IL-1 levels. Serum IL-1 concentration was lower in the challenged birds fed YCW as compared to control or AB but no effect of additive treatment was observed in unchallenged birds. Necrotic enteritis challenge led to higher serum IL-1 concentration in both control and AB fed birds but not in those fed YCW. Neither challenge nor additive had a significant effect on IL-10 concentration.

Elevated levels of IgG were detected in the NE challenge group compared to unchallenged group ($P < 0.01$). Regardless of challenge, birds supplemented with YCW had higher IgG ($P < 0.05$) and IgM ($P < 0.05$) levels compared to groups fed the control diet or diet supplemented with AB. Treatment had no significant effect on serum IgA level ($P > 0.05$).

A challenge \times additive interaction ($P < 0.001$) was observed for liver weight. In challenged birds, liver weights of AB fed birds were higher than bird fed YCW or controls whereas in unchallenged birds liver weights were not different ($P > 0.05$) among additives.

3.4. Short chain fatty acids

Table 6 shows the concentrations of 9 SCFA measured in the ceca at d 16. Challenge \times additive interactions were observed for formic acid ($P < 0.05$) and butyric acid ($P < 0.05$). Without challenge, both AB and YCW fed groups showed higher cecal formic acid concentrations compared to controls, and under NE challenge, the birds fed the AB diet showed lower cecal formic acid concentrations than YCW fed birds but no difference from birds fed the control diet. Challenged birds had lower levels of formic acid compared to unchallenged birds across additive groups. In unchallenged birds, cecal butyric acid levels of YCW fed birds were higher than birds fed AB or controls but there were no additive effects in challenged birds. Cecal propionic acid concentrations were higher ($P < 0.01$) and valeric acid concentrations lower ($P < 0.01$) in unchallenged birds compared to challenged birds. Isovaleric acid concentration was higher ($P < 0.05$) in birds fed the control diet or YCW compared to AB.

Table 2
Performance of broilers from d 0 to 24.

Interactions		Feed intake, g/bird	Weight gain, g/bird	FCR, g/g	Livability, %
Challenge	Additives ¹				
No	None	1,710	1,351 ^a	1.265	98
No	YCW	1,698	1,356 ^a	1.251	99
No	AB	1,692	1,361 ^a	1.243	98
Yes	None	1,653	1,241 ^b	1.333	98
Yes	YCW	1,643	1,242 ^b	1.324	95
Yes	AB	1,684	1,320 ^a	1.279	97
SEM		10.9	9.7	0.006	0.6
Main effects					
Challenge					
No		1,700	1,356 ^a	1.253 ^b	98
Yes		1,660	1,267 ^b	1.312 ^a	97
Additives					
None		1,682	1,296 ^b	1.299 ^a	98
YCW		1,671	1,299 ^b	1.288 ^a	97
AB		1,688	1,341 ^a	1.261 ^b	98
P-value					
Challenge		0.072	<0.001	<0.001	0.168
Additive		0.803	0.012	0.002	0.791
Challenge × Additive		0.590	0.046	0.170	0.369

FCR = feed conversion ratio; YCW = yeast cell wall extract; AB = antibiotics.

^{a, b} Means not sharing the same superscripts are significantly different ($P < 0.05$).¹ None = basal diet (no additive); YCW = basal diet + YCW (Actigen, Alltech, USA); AB = basal diet + Zn bacitracin (Albac 150) + salinomycin (Sacox 120).**Table 3**
Performance of broilers from d 0 to 35.

Interactions		Feed intake, g/bird	Weight gain, g/bird	FCR, g/g	Livability, %
Challenge	Additives ¹				
No	None	3,601	2,501	1.441	98
No	YCW	3,600	2,516	1.431	97
No	AB	3,505	2,521	1.390	98
Yes	None	3,668	2,501	1.466	98
Yes	YCW	3,680	2,499	1.474	95
Yes	AB	3,591	2,539	1.414	95
SEM		23.2	14.5	0.006	0.6
Main effects					
Challenge					
No		3,568	2,513	1.421 ^b	98
Yes		3,646	2,513	1.451 ^a	96
Additives					
None		3,634	2,501	1.454 ^a	98
YCW		3,640	2,508	1.453 ^a	96
AB		3,548	2,530	1.402 ^b	97
P-value					
Challenge		0.098	0.995	0.004	0.186
Additive		0.199	0.723	<0.001	0.399
Challenge × Additive		0.986	0.894	0.689	0.607

FCR = feed conversion ratio; YCW = yeast cell wall extract; AB = antibiotics.

^{a, b} Means not sharing the same superscripts are significantly different ($P < 0.05$).¹ None = basal diet (no additive) YCW = basal diet + YCW (Actigen, Alltech, USA); AB = basal diet + Zn bacitracin (Albac 150) + salinomycin (Sacox 120).

4. Discussion

In this study, only AB supplementation improved performance of broilers under subclinical NE challenge. A successful subclinical NE was induced as confirmed by poor performance, presence of mild lesions and lack of mortality (Gholamiandehkordi et al., 2007). In a previous study, both YCW and AB improved performance (FI, BWG, FCR) during clinical NE challenge (M'Sadeq et al., 2015). This might suggest that the intensity of NE challenge affects the efficacy of YCW. Other evidence exists showing YCW had little effect on performance loss during Cp or coccidial infection (Hofacre et al., 2003; Nollet et al., 2007; Ao et al., 2012; Shanmugasundaram et al., 2013). This low impact of YCW on intestinal lesion scores in this study was similar to that reported by Ao et al. (2012) and Hofacre et al. (2003). However M'Sadeq et al. (2015) observed improved performance by YCW under clinical NE challenge, it did

not influence intestinal lesion scores. It is logical that alleviation of intestinal lesions would relieve the impact of NE because intact gut morphology would maintain nutrient absorption. Perhaps YCW does not affect the colonization of Cp on the intestinal epithelium directly, i.e., lesion development, but rather may have other roles, for example, immunity of the birds, that determine different performance responses in clinical or subclinical NE outbreaks.

Immunomodulation as a result of dietary YCW has been postulated and the current study showed YCW exhibited anti-inflammatory effects and promoted Ig production. Inflammation is an important but often overlooked consequence of NE. This study showed that NE elevated the pro-inflammatory cytokine level, which is supported by previous reports (Park et al., 2008). Inflammation can reset priority of physiological and developmental processes to prepare the host to fight infection (Klasing, 1988). Specifically, inflammation impairs FI, absorption of nutrients

Table 4

Duodenum, jejunum and ileum NE lesion score at d 16.

Interactions		Duodenum	Jejunum	Ileum
Challenge	Additives ¹			
No	None	0.00	0.00	0.00 ^b
No	YCW	0.00	0.00	0.00 ^b
No	AB	0.00	0.00	0.00 ^b
Yes	None	0.00	0.13	0.47 ^a
Yes	YCW	0.09	0.13	0.25 ^{ab}
Yes	AB	0.03	0.00	0.13 ^b
SEM		0.016	0.025	0.047
Main effects				
Challenge				
No		0.00	0.00	0.00 ^b
Yes		0.04	0.08	0.28 ^a
Additives				
None		0.00	0.06	0.23
YCW		0.05	0.06	0.13
AB		0.02	0.00	0.06
P-value				
Challenge		0.153	0.077	<0.001
Additive		0.600	0.367	0.228
Challenge × Additive		0.537	0.211	0.003

YCW = yeast cell wall extract; AB = antibiotics.

^{a, b} Means not sharing the same superscripts are significantly different ($P < 0.05$).¹ None = basal diet (no additive); YCW = basal diet + YCW (Actigen, Alltech, USA); AB = basal diet + Zn bacitracin (Albac 150) + salinomycin (Sacox 120).**Table 5**

Serum interleukins response (IL-1 and IL-10, pg/mL), immunoglobulins (IgA, IgG and IgM, mg/mL) and average liver weights as a percent of live body weight (g/g, %) of broilers at d 16.

Interactions		IL-1	IL-10	IgA	IgG	IgM	Liver
Challenge	Additives ¹						
No	None	103 ^b	1.13	4.7	3.4	1.7	3.33 ^{cd}
No	YCW	99 ^b	1.15	6.1	4.1	2.1	3.32 ^{cd}
No	AB	102 ^b	1.17	4.0	3.3	1.9	3.28 ^d
Yes	None	120 ^a	1.16	6.3	3.9	1.8	3.59 ^b
Yes	YCW	106 ^b	1.16	6.1	4.5	2.3	3.50 ^{bc}
Yes	AB	126 ^a	1.23	5.1	4.3	1.6	4.03 ^a
SEM		1.9	0.024	0.38	0.12	0.08	0.053
Main effects							
Challenge							
No		101 ^b	1.15	5.0	3.6 ^b	1.9	3.31 ^b
Yes		117 ^a	1.18	5.8	4.2 ^a	1.9	3.71 ^a
Additives							
None		112 ^a	1.15	5.5	3.6 ^b	1.8 ^b	3.46 ^b
YCW		103 ^b	1.15	6.1	4.3 ^a	2.2 ^a	3.41 ^b
AB		114 ^a	1.20	4.5	3.8 ^b	1.7 ^b	3.66 ^a
P-value							
Challenge		<0.001	0.522	0.263	0.002	0.983	<0.001
Additive		0.002	0.698	0.267	0.018	0.012	0.004
Challenge × Additive		0.040	0.921	0.734	0.469	0.318	<0.001

YCW = yeast cell wall extract; AB = antibiotics.

^{a-d} Means not sharing the same superscripts are significantly different ($P < 0.05$).¹ None = basal diet (no additive); YCW = basal diet + YCW (Actigen, Alltech, USA); AB = basal diet + Zn bacitracin (Albac 150) + salinomycin (Sacox 120).

anabolic processes in order to divert nutrients toward tissues involved in immunity, fever and hepatic production of acute phase protein (Klasing et al., 1987; Klasing, 2005). This implies that the cost of NE consists of 2 parts – a dysfunctional intestine and the cost of immunity respectively. The cost of immunity may contribute more to productivity loss during subclinical NE when intestinal damage is mild (Gholamiandehkordi et al., 2007) and thus anti-inflammation could be expected to resolve loss from subclinical NE. It is interesting to find that YCW showed stronger anti-inflammatory effects than AB or control diet in the present study, which was also reflected in the lower liver relative weight because enlarged liver can be induced by system inflammation (Lichtman et al., 1990). Ferket et al. (2002) also observed birds fed YCW product had lighter liver than those fed a diet with antibiotics under lipopolysaccharide challenge. Yeast cell wall extract has also

been reported to terminate systemic inflammation earlier than virginiamycin in the findings of Baurhoo et al. (2012). It is likely that YCW competitively excludes pathogens whose cell integrity will be maintained whereas the use of antibiotics results in bacterial fragmentation during cytolysis (Yamasaki et al., 2009). This would lead to release of cellular contents, including microbial DNA and prototypical enterotoxins (Su et al., 2006) thus inducing inflammatory response. On the other hand, in this study YCW promoted Ig secretion to be suggested that might offer protection against the infection (Cetin et al., 2005; Czech et al., 2010). Moreover, YCW increased butyric acid and formic acid production in the ceca. To some extent, SCFA control bacterial infections, act as potential antibiotic replacers, and benefit the gut health as an energy source for enterocytes (Hernández et al., 2006; García et al., 2007; Fernández-Rubio et al., 2009).

Table 6
Short chain fatty acids levels in caecal contents at d 16 ($\mu\text{mol/g}$ digesta).

Interactions		Formic	Acetic	Propionic	Isobutyric	Butyric	Isovaleric	Valeric	Lactic	Succinic
Challenge	Additives ¹									
No	None	0.73 ^b	57.81	21.66	0.86	11.71 ^b	0.31	1.13	0.61	3.86
No	YCW	1.05 ^a	76.92	30.08	1.02	18.73 ^a	0.38	1.67	0.83	1.93
No	AB	1.19 ^a	68.23	25.78	0.61	15.00 ^b	0.20	1.27	1.04	3.31
Yes	None	0.43 ^{cd}	82.19	14.66	0.85	21.50 ^a	0.31	2.29	0.67	2.17
Yes	YCW	0.66 ^{bc}	74.20	15.38	0.71	20.72 ^a	0.20	1.97	0.53	4.14
Yes	AB	0.31 ^d	83.01	15.29	0.59	21.05 ^a	0.16	2.13	1.18	3.35
SEM		0.064	3.189	1.600	0.054	0.719	0.023	0.115	0.088	0.524
Main effects										
Challenge										
No		0.99 ^a	67.66	25.84 ^a	0.83	15.15 ^b	0.30	1.36 ^b	0.82	3.03
Yes		0.47 ^b	79.80	15.11 ^b	0.72	21.09 ^a	0.22	2.13 ^a	0.79	3.22
Additives										
None		0.58 ^b	70.00	18.16	0.85	16.60 ^b	0.31 ^a	1.71	0.64	3.02
YCW		0.86 ^a	75.56	22.73	0.87	19.73 ^a	0.29 ^a	1.82	0.68	3.04
AB		0.75 ^{ab}	75.62	20.53	0.60	18.03 ^{ab}	0.18 ^b	1.7	1.11	3.33
P-value										
Challenge		<0.001	0.058	0.005	0.281	<0.001	0.085	0.005	0.854	0.863
Additive		0.044	0.693	0.414	0.069	0.045	0.037	0.856	0.057	0.965
Challenge \times Additive		0.024	0.208	0.533	0.424	0.010	0.251	0.218	0.551	0.352

YCW = yeast cell wall extract; AB = antibiotics.

^{a-d} Means not sharing the same superscripts are significantly different ($P < 0.05$).

¹ None = basal diet (no additive); YCW = basal diet + YCW (Actigen, Alltech, USA); AB = basal diet + Zn bacitracin (Albac 150) + salinomycin (Sacox 120).

There could be numerous reasons why YCW did not improve performance during subclinical NE. It is possible that YCW supplementation suppressed inflammation temporarily but pro-inflammatory response started to occur after continuously feeding of YCW. Prolonged provision of dietary YCW increased the IL-6 level, a pro-inflammatory cytokine, a week after Cp challenge (Ao et al., 2012). Tzianabos (2000) also suggested β -glucan derived from YCW is potent to prime and activate inflammatory responses. Thus, it may suggest that feeding YCW may help the bird adjust its priority of response, i.e., anti- or pro-inflammation, depending on the lumen environment or severity of the disease, which may largely determine the performance response (Klasing et al., 1987). This hypothesis can be supported by the findings of Huff et al. (2006) who found β -glucan only improved performance of broilers during an *Escherichia coli* challenge and such improvement diminished when β -glucan was given to the challenged birds continuously. Moreover, in the same study, β -glucan reduced BW without the presence of challenge that suggested stimulating immunity by β -glucan was costly to production and may need to be cautious to use under a challenge-free environment. This might explain why YCW is more effective on performance under clinical rather than subclinical NE challenge when the syndrome is milder and recovery is faster. Furthermore, it is logical that Ig secretion is an energetically expensive. The proliferation of Ig secreting lymphocytes was promoted under a conventional husbandry condition but not under a germ-free, antigen-free practices where results in better growth performance (Hooijkaas et al., 1984; Furuse and Yokota, 1985; Pereira et al., 1986; Bos et al., 1988; Bakker et al., 1995). Moreover, SCFA are not necessarily beneficial to gut integrity and production as Nafday et al. (2005) and Liu et al. (2014) proved colonic mucosal injury and weight loss can be mediated by administration of SCFA such as butyric acid in rats or goat. It was of interest that in the current experiment YCW increased butyrate levels in the hindgut in the unchallenged group yet resulted in increased formate in the hindgut of challenged birds. It was hypothesized that the increased butyrate caused by YCW in unchallenged birds may be metabolized into formate during challenge. Further work is warranted to test this hypothesis.

Gut health management is an important strategy to maintain productivity in the poultry industry in the post-antibiotic era. The

use of prebiotics is one such strategy that has gained attention over recent years (Patterson and Burkholder, 2003) but there remains tremendous variation in their efficacy (Santin et al., 2001; Benites et al., 2008; Midilli et al., 2008). There are many possible reasons for this variability in efficacy, including the type of prebiotics used, the gut microflora, feed, chicken breed, age of birds, husbandry environment, and management practice. More work is required to elucidate each of these variables in more extensive settings.

5. Conclusion

Supplementation of YCW may offer protection against subclinical NE due to its effects on anti-inflammation, immunoglobulin secretion and SCFA production. However, continuous feeding of YCW, especially after birds have recovered from subclinical NE, may diminish the positive effect of YCW on performance. The current study showed the range and regime of YCW that may be deployed under antibiotic-free production situations.

Conflict of interest

The authors declare that they have no conflict of interest.

Acknowledgements

The senior author was thankful to be given this opportunity to work on the project as a student assistant before the official commencement of his PhD. We also thank Natalie Morgan (Animal Science, School of Environmental and Rural Sciences, University of New England, Australia) for proofreading. University of New England (Australia) and all the technician team and members of the Poultry Research and Teaching group are recognized for technical support and help during this study. Alltech (USA) is gratefully acknowledged for funding this project (13-E-9150).

References

- Ao Z, Kocher A, Choct M. Effects of dietary additives and early feeding on performance, gut development and immune status of broiler chickens challenged with *Clostridium perfringens*. *Asian-australas J Anim Sci* 2012;25:541–51.
- Aviagen. Broiler nutrition specification Ross 308. Huntsville, Alabama, USA. 2014.

- Bakker R, Lasonder E, Bos NA. Measurement of affinity in serum samples of antigen-free, germ-free and conventional mice after hyperimmunization with 2, 4-dinitrophenyl keyhole limpet hemocyanin, using surface plasmon resonance. *Eur J Immunol* 1995;25:1680–6.
- Baurhoo B, Ferket P, Ashwell CM, de Oliveira J, Zhao X. Cell walls of *Saccharomyces cerevisiae* differentially modulated innate immunity and glucose metabolism during late systemic inflammation. *PLoS One* 2012;7, e30323.
- Benites V, Gilhary R, Gernat AG, Murillo JG. Effect of dietary mannan oligosaccharide from Bio-Mos or SAF-Mannan on live performance of broiler chickens. *J Appl Poult Res* 2008;17:471–5.
- Bos NA, Meeuwssen CG, Wostmann BS, Pleasants JR, Benner R. The influence of exogenous antigenic stimulation on the specificity repertoire of background immunoglobulin-secreting cells of different isotypes. *Cell Immunol* 1988;112:371–80.
- Broussard CT, Hofacre CL, Page RK, Fletcher OJ. Necrotic enteritis in cage-reared commercial layer pullets. *Avian Dis* 1986;30:617–9.
- Callaway TR, Edrington TS, Anderson RC, Harvey RB, Genovese KJ, Kennedy CN, et al. Probiotics, prebiotics and competitive exclusion for prophylaxis against bacterial disease. *Anim Health Res Rev* 2008;9:217–25.
- Cetin N, Güçlü BK, Cetin E. The effects of probiotic and mannanoligosaccharide on some haematological and immunological parameters in turkeys. *Transbound Emerg Dis* 2005;52:263–7.
- Chen YS, Sriannual S, Onda T, Yanagida F. Effects of prebiotic oligosaccharides and trehalose on growth and production of bacteriocins by lactic acid bacteria. *Lett Appl Microbiol* 2007;45:190–3.
- Czech A, Grela ER, Mokrzycka A, Pejsak Z. Efficacy of mannanoligosaccharides additive to sows diets on colostrum, blood immunoglobulin content and production parameters of piglets. *Pol J Vet Sci* 2010;13:525–31.
- Desmidt M, Ducatelle R, Mast J, Goddeeris BM, Kaspers B, Haesebrouck F. Role of the humoral immune system in *Salmonella enteritidis* phage type four infection in chickens. *Vet Immunol Immunopathol* 1998;63:355–67.
- Donalson LM, Kim WK, Chalova VI, Herrera P, McReynolds JL, Gotcheva VG, et al. In vitro fermentation response of laying hen cecal bacteria to combinations of fructooligosaccharide prebiotics with alfalfa or a layer ration. *Poult Sci* 2008;87:1263–75.
- Ferket PR, Parks CW, Grimes JL. Benefits of dietary antibiotic and mannanoligosaccharide supplementation for poultry. In: Proc. multi-state poultry meeting; 2002.
- Fernández-Rubio C, Ordóñez C, Abad-González J, Garcia-Gallego A, Pilar Honrubia M, Jose Mallo J, et al. Butyric acid-based feed additives help protect broiler chickens from *Salmonella Enteritidis* infection. *Poult Sci* 2009;88:943–8.
- Furuse M, Yokota H. Effect of the gut microflora on chick growth and utilisation of protein and energy at different concentrations of dietary protein. *Br Poult Sci* 1985;26:97–104.
- Gao J, Zhang HJ, Yu SH, Wu SG, Yoon I, Quigley J, et al. Effects of yeast culture in broiler diets on performance and immunomodulatory functions. *Poult Sci* 2008;87:1377–84.
- García V, Catalá-Grego P, Hernández F, Megías MD, Madrid J. Effect of formic acid and plant extracts on growth, nutrient digestibility, intestine mucosa morphology, and meat yield of broilers. *J Appl Poult Res* 2007;16:555–62.
- Gholamiandehkordi AR, Timbermont L, Lanckriet A, Broeck WVD, Pedersen K, Dewulf J, et al. Quantification of gut lesions in a subclinical necrotic enteritis model. *Avian Pathol* 2007;36:375–82.
- Goudswaard J, Noordzij A, Van Dam RH, Van Der Donk JA, Vaerman J-P. The immunoglobulins of the Turkey (*Meleagris gallopavo*). Isolation and characterization of IgG, IgM and IgA in body fluids, eggs and intraocular tissues. *Poult Sci* 1977;56:1847–51.
- Hernández F, García V, Madrid J, Orengo J, Catalá P, Megías MD. Effect of formic acid on performance, digestibility, intestinal histomorphology and plasma metabolite levels of broiler chickens. *Br Poult Sci* 2006;47:50–6.
- Hofacre CL, Beacom T, Collett S, Mathis G. Using competitive exclusion, mannanoligosaccharide and other intestinal products to control necrotic enteritis. *J Appl Poult Res* 2003;12:60–4.
- Hooijkaas H, Benner R, Pleasants JR, Wostmann BS. Isotypes and specificities of immunoglobulins produced by germ-free mice fed chemically defined ultra-filtered “antigen-free” diet. *Eur J Immunol* 1984;14:1127–30.
- Huff GR, Huff WE, Rath NC, Tellez G. Limited treatment with β -1, 3/1, 6-glucan improves production values of broiler chickens challenged with *Escherichia coli*. *Poult Sci* 2006;85:613–8.
- Jensen MT, Cox RP, Jensen BB. Microbial production of skatole in the hind gut of pigs given different diets and its relation to skatole deposition in backfat. *Anim Sci* 1995;61:293–304.
- Kaldhusdal M, Schneitz C, Hofshagen M, Skjerv E. Reduced incidence of *Clostridium perfringens*-associated lesions and improved performance in broiler chickens treated with normal intestinal bacteria from adult fowl. *Avian Dis* 2001;45:149–56.
- Klasing KC. Nutritional aspects of leukocytic cytokines. *J Nutr* 1988;118:1436–46.
- Klasing KC. Interplay between diet, microbes, and immune defenses of the gastrointestinal tract. In: Starck JM, Wang T, editors. Physiological and ecological adaptations to feeding in vertebrates. Enfield, New Hampshire: Science; 2005. p. 229–54.
- Klasing KC, Laurin DE, Peng RK, Fry DM. Immunologically mediated growth depression in chicks: influence of feed intake, corticosterone and interleukin-1. *J Nutr* 1987;117:1629–37.
- Lichtman SN, Sartor RB, Keku J, Schwab JH. Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth. *Gastroenterology* 1990;98:414–23.
- Liu J, Xu T, Zhu W, Mao S. High-grain feeding alters caecal bacterial microbiota composition and fermentation and results in caecal mucosal injury in goats. *Brit J Nutr* 2014;112:416–27.
- M'Sadeq SA, Wu SB, Choct M, Forder R, Swick RA. Use of yeast cell wall extract as a tool to reduce the impact of necrotic enteritis in broilers. *Poult Sci* 2015;94:898–905.
- Medzhitov R. Recognition of microorganisms and activation of the immune response. *Nature* 2007;449:819–26.
- Midilli M, Alp M, Kocabagli N, Muglali Ö, Turan N, Yilmaz H, Çakir S. Effects of dietary probiotic and prebiotic supplementation on growth performance and serum IgG concentration of broilers. *S Afr J Anim Sci* 2008;38:21–7.
- Monsan PF, Paul F. Oligosaccharide feed additives. In: Wallace RJ, Chesson A, editors. Biotechnology in animal feeds and animal feeding. John Wiley & Sons; 2008. p. 233–45.
- Muñoz M, Mosquera A, Alméjida-Díaz C, Melendez AP, Sánchezc OF. Fructooligosaccharides metabolism and effect on bacteriocin production in *Lactobacillus* strains isolated from ensiled corn and molasses. *Anaerobe* 2012;18:321–30.
- Nafday SM, Chen W, Peng L, Babyatsky MW, Holzman IR, Lin J. Short-chain fatty acids induce colonic mucosal injury in rats with various postnatal ages. *Pediatr Res* 2005;57:201–4.
- Nollet L, Huyghebaert G, Spring P. Effect of dietary mannan oligosaccharide (Bio-Mos) on live performance of broiler chickens given an anticoccidial vaccine (Paracox) followed by a mild coccidial challenge. *J Appl Poult Res* 2007;16:397–403.
- Park SS, Lillehoj HS, Allen PC, Park DW, FitzCoy S, Bautista DA, et al. Immunopathology and cytokine responses in broiler chickens coinfecting with *Eimeria maxima* and *Clostridium perfringens* with the use of an animal model of necrotic enteritis. *Avian Dis* 2008;52:14–22.
- Patterson JA, Burkholder KM. Application of prebiotics and probiotics in poultry production. *Poult Sci* 2003;82:627–31.
- Pereira P, Forni L, Larsson EL, Cooper M, Heusser C, Coutinho A. Autonomous activation of B and T cells in antigen-free mice. *Eur J Immunol* 1986;16:685–8.
- Pourabedin M, Zhao X. Probiotics and gut microbiota in chickens. *FEMS Microbiol Lett* 2015;362:fnv122.
- Prescott JF, Sivendra R, Barnum DA. The use of bacitracin in the prevention and treatment of experimentally-induced necrotic enteritis in the chicken. *Can Vet J* 1978;19:181–3.
- Santin E, Maiorka A, Macari M, Grecco M, Sanchez JC, Okada TM, et al. Performance and intestinal mucosa development of broiler chickens fed diets containing *Saccharomyces cerevisiae* cell wall. *J Appl Poult Res* 2001;10:236–44.
- Shanmugasundaram R, Sifri M, Selvaraj RK. Effect of yeast cell product (CitriStim) supplementation on broiler performance and intestinal immune cell parameters during an experimental coccidial infection. *Poult Sci* 2013;92:358–63.
- Shashidhara RG, Devegowda G. Effect of dietary mannan oligosaccharide on broiler breeder production traits and immunity. *Poult Sci* 2003;82:1319–25.
- Shojadoost B, Vince AR, Prescott JF. The successful experimental induction of necrotic enteritis in chickens by *Clostridium perfringens*: a critical review. *Vet Res* 2012;43:74.
- Su SC, Hua KF, Lee H, Chao LK, Tan SK, Yang SF, et al. LTA and LPS mediated activation of protein kinases in the regulation of inflammatory cytokines expression in macrophages. *Clin Chim Acta* 2006;374:106–15.
- Timbermont L, Haesebrouck F, Ducatelle R, Van Immerseel F. Necrotic enteritis in broilers: an updated review on the pathogenesis. *Avian Pathol* 2011;40:341–7.
- Tzianabos AO. Polysaccharide immunomodulators as therapeutic agents: structural aspects and biologic function. *Clin Microbiol Rev* 2000;13:523–33.
- Van der Sluis W. Clostridial enteritis—a syndrome emerging world-wide. *World Poult* 2000;16:56–7.
- Wade B, Keyburn A. The true cost of necrotic enteritis. *World Poult* 2015;31:16–7.
- Yamasaki M, Nakamura K, Tamura N, Hwang S-J, Yoshikawa M, Sasaki N, et al. Effects and mechanisms of action of ionophorous antibiotics valinomycin and salinomycin-Na on *Babesia gibsoni* in vitro. *J Parasitol* 2009;95:1532–8.